Quick Takeaways
- GILEAD SCIENCES, INC. filed SCHEDULE 13G/A for Kalaris Therapeutics, Inc. Common Stock, $0.0001 per value (KLRS).
- Disclosed ownership: 3.9%.
- Date of event: 18 Mar 2025.
GILEAD SCIENCES, INC. - 18 Mar 2025 SCHEDULE 13G/A Report for Kalaris Therapeutics, Inc. Common Stock, $0.0001 per value (KLRS)
- Filing Manager
- GILEAD SCIENCES, INC.
- Reporting Manager
- GILEAD SCIENCES, INC.
- Symbol
- KLRS
- Shares outstanding
- 18,545,462 shares
- Disclosed Ownership
- 723,273 shares
- Ownership
- 3.9%
- Form type
- SCHEDULE 13G/A
- Filing time
- 20 Mar 2025, 16:32:25 UTC
- Date of event
- 18 Mar 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"GILEAD SCIENCES, INC. disclosed 3.9% ownership in Kalaris Therapeutics, Inc. Common Stock, $0.0001 per value (KLRS) on 18 Mar 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 20 Mar 2025, 16:32.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 3.9% | 723,273 | 723,273 | 0 | /s/ Andrew D. Dickinson | Andrew D. Dickinson, Executive Vice President and Chief Financial Officer |